China
Africa
Explore chapters and articles related to this topic
Neuromodulators and Fillers
Published in Alexander Berlin, Mohs and Cutaneous Surgery, 2014
Suneel Chilukuri, Sailesh Konda, Sean Bury
Poly-L-Lactic Acid PLLA was initially approved for the treatment of HIV-associated lipodystrophy. It consists of microparticles suspended in a degradable gel. As the gel is slowly resorbed following implantation, PLLA upregulates fibroblasts to produce new collagen. This makes the filler both long-lasting, persisting for up to 2 years, and slow-acting, with final results often taking several months to manifest.59
HIV
Published in John W. Scadding, Nicholas A. Losseff, Clinical Neurology, 2011
A syndrome called HIV-associated lipodystrophy syndrome is increasingly common with the use of HAART. The syndrome comprises two components: a change in body fat distribution with peripheral fat atrophy and central fat accumulation, together with metabolic abnormalities of hyper-lipidaemia and insulin resistance. The syndrome is thought to be a combination of the effects of PIs causing fat accumulation, high lipids and insulin resistance, and nRTIs causing lipoatrophy.
Effect of lipodystrophy on self-esteem and adherence to antiretroviral therapy in people living with HIV
Published in AIDS Care, 2022
Larissa Rodrigues Siqueira, Gilmara Holanda da Cunha, Marli Teresinha Gimeniz Galvão, Marina Soares Monteiro Fontenele, Franscisco Vagnaldo Fechine, Melissa Soares Medeiros, Lavna Albuquerque Moreira
In this context, although HIV-associated lipodystrophy needs further elucidation as to the totality of its pathophysiological mechanism, its occurrence is related to the presence of pro-inflammatory cytokines, viral infection, genetic factors and antiretroviral drugs (Grenha et al., 2016). ART can increase the risk of lipodystrophy 13 times or more, especially if stavudine is used for an extended period, with a threefold greater chance of lipodystrophic changes (Njelekela et al., 2017). Studies have found that lipodystrophy is the most prevalent adverse event among PLHIV on ART (Abah et al., 2018).